BlackRock, Inc. Increases Stake in ANI Pharmaceuticals Inc.

BlackRock, Inc. has filed a Schedule 13G/A amendment with the SEC, disclosing an increased ownership stake in ANI Pharmaceuticals Inc. As of September 30, 2025, BlackRock beneficially owns 2,517,424 shares of ANI Pharmaceuticals' common stock, representing an 11.3% ownership interest. This marks a significant increase from previous filings, with the value of the holdings rising by 98.27% to $2,923,132,051.84. The filing indicates that BlackRock acquired these shares in the ordinary course of business and not with the intent to influence control of the issuer. The shares are held by various business units of BlackRock, and no single entity owns more than 5% of the total outstanding shares. The filing was signed by Spencer Fleming, Managing Director of BlackRock, Inc.